An Oral Antioxidant Formulation Delaying and Potentially Reversing Canine Diabetic Cataract: A Placebo-controlled Double-masked Pilot Study

Background: The majority of dogs with diabetes mellitus develop blinding mature cataracts through the action of the enzyme aldose reductase producing sorbitol with osmotic action drawing water into the lens thus causing opacification. Here we evaluate the use of OcuGLO™ a formulation including the aldose reductase inhibitor alpha lipoic acid, grapeseed extract, carotenoids, omega-3-fatty acids, and coenzyme Q10 in the prevention of canine diabetic cataract in a prospective placebo-controlled double-masked study. Materials and methods: Dogs with diabetes mellitus but as yet without the development of blinding diabetic cataracts were given either OcuGLO™ or a placebo containing antioxidant vitamins. Dogs were examined monthly and their degree of lens opacification documented photographically using a Genesis D fundus camera at +10D. Time to progression of lens opacification was documented and compared between the OcuGLO™ group and the placebo group, using Kaplan Meier survival curve statistics. Results: Mean time without change in lens opacification was 278 ± 184 days with OcuGLO Rx™ and 77 ± 40 days in the placebo group this difference being statistically significant at p=0.0005. Twelve of 15 dogs taking the placebo developed significantly increased lens opacification while 5 of 15 dogs taking OcuGLO Rx™ developed significant cataract. of these five dogs four animals did not receive daily OcuGLO Rx™ as directed due to unrelated concurrent illness or owner non-compliance. The remaining dog progressed despite Ocu-GLO Rx™ administration. In two dogs, diabetic cataract was reversed with regained vision on Ocu-GLO Rx™. Discussion: This small preliminary study demonstrates that oral Ocu-GLO Rx™ has beneficial effects in delaying cataract formation in dogs with diabetes mellitus. We look forward to further studies with larger case populations but note that the statistical significance reached between placebo and supplement-treated group, even with a small study population, demonstrates the efficacy of this commercially available dietary supplement.